Nephrology

The 2020 Kidney Disease: Improving Global Outcomes Clinical Practice Guideline integrates new treatments and practices with existing management strategies for CKD patients with diabetes.

Dapagliflozin is the first SGLT-2 inhibitor to receive FDA approval for the treatment of CKD, regardless of diabetes status.

ACP: Clyde W Yancy, MD, gave a comprehensive update on a year's worth of pivotal science in treatment of heart failure. Here are the highlights.

Video: George Bakris, MD says over the next 3 years there is going to be an "explosion" in the number of studies we see in heart failure, diabetic kidney disease, and CV risk in general.

The most popular features in preventive cardiology this year were interviews with thought leaders on management of diabetes, hypertension, and hypercholesterolemia.

Patients with chronic kidney disease have had no treatment options to slow the certain progression to renal failure. Enter SGLT2 inhibitors. A key clinical trial investigator explains.

Primary care clinicians should be the first to prescribe SGLT2 inhibitors for many reasons, as explained by Prof Jonathan McMurray in this Patient Care interview.

DAPA-CKD investigator Professor John McMurray details the trial and renal and cardiovascular outcomes for Patient Care Online.

AHA: DAPD-CKD investigator Prof John McMurray talks to Patient Care about the “revolutionary” findings he will highlight at the AHA sessions on opening day.

Finerenone, a non-steroidal, selective MRA, has distinct advantages over current treatments for diabetic kidney disease. Dr Bakris details these and the FIDELIO results.

Waist circumference measures, complementary antihypertensives, appropriate exercise levels for T2D patients--test what you know about cardiometabolic risk and management.

Dapagliflozin is renoprotective and cardioprotective in chronic kidney disease patients, suggests a secondary analysis of the DAPA-CKD trial presented at Kidney Week 2020.

The investigational mineralocorticoid receptor antagonist slowed progression to renal failure by 18% and reduced the composite cardiovascular outcome by 14%, authors report.

FDA Fast Track designation is to investigate whether the diabetes medication can also reduce kidney disease progression.

Cardiovascular diseases, particularly heart failure, were found significantly and independently associated with end-stage renal disease in a new analysis.

When CKD 4-5 progresses to ESRD, how should hypertension management be changed? Or, should it?

New risk prediction models may help identify patients with and without diabetes at elevated risk for chronic kidney disease, say authors of a recent study.

Transitioning from urgent, unplanned inpatient dialysis to home hemodialysis was linked to higher risk of mortality in a new registry analysis.

A new prospective analysis of ADPKD guidelines from Canada and Europe resulted in cohorts enriched with high-risk patients in excess of 80%.

Results of a new study may put to rest the suggestion that vitamin D or omega-3 fatty acids protect against incident kidney disease or disease progression.

According to a new report based on hospital encounters, autosomal dominant polycystic kidney disease is not a significant risk factor for kidney stones.

Highlighted: Chronic kidney disease and stroke risk, syphilis in ESRD patients, and how healthy diets may reduce CKD incidence.

Primary care providers are often first to detect chronic kidney disease and essential to help prevent complications. Take our short test on CKD basics.

Lack of knowledge, keeping up with changing management guidelines, and limited time and resources were among reported barriers. 

Studies on comorbidities seen with CKD reviewed here examine controlled vs uncontrolled gout, psychiatric diagnoses, and screening for intracranial aneurysm.